{"entity":{"id":"bd200","kind":"drug","name":"BD200","aka":[],"tldr":"BD200 is an experimental multibody-drug conjugate from Biolojic Design, in phase 1 trials for select unresectable locally advanced or metastatic solid cancers.","summary":"BD200 is a multibody-drug conjugate (dual-binding IgG antibody-drug conjugate) from Biolojic Design. A 'two-in-one' antibody in which each arm can bind either TROP-2 (TROP2) or Nectin-4, used as the base of an antibody-drug conjugate. Its furthest stage is phase 1, for select unresectable locally advanced or metastatic solid cancers. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT07797907 not yet recruiting; estimated start 31 December 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Biolojic Design: biolojic.com","url":"https://biolojic.com/pipeline/"},{"label":"Biolojic Design: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07797907"},{"label":"ClinicalTrials.gov: trials of BD200","url":"https://clinicaltrials.gov/search?intr=BD200"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2","nectin4"],"drugs":[],"companies":["biolojic-design"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07797907"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BD200","modality":"Multibody-drug conjugate (dual-binding IgG antibody-drug conjugate)","mechanism":"A 'two-in-one' antibody in which each arm can bind either TROP-2 (TROP2) or Nectin-4, used as the base of an antibody-drug conjugate.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bd200/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"biolojic-design","kind":"company","name":"Biolojic Design","route":"/companies/biolojic-design/"}],"trial":[{"id":"nct07797907","kind":"trial","name":"This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.","route":"/trials/nct07797907/"}]}}